Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cryptococcosis | 28 | 2019 | 43 | 9.090 |
Why?
|
| Cryptococcus neoformans | 27 | 2017 | 62 | 7.890 |
Why?
|
| Lung Diseases, Fungal | 12 | 2015 | 21 | 3.290 |
Why?
|
| Fungal Vaccines | 10 | 2017 | 44 | 2.780 |
Why?
|
| Macrophage Activation | 7 | 2015 | 59 | 2.020 |
Why?
|
| Mice, Inbred BALB C | 21 | 2019 | 686 | 1.620 |
Why?
|
| Lung | 10 | 2019 | 484 | 1.420 |
Why?
|
| Dendritic Cells | 3 | 2019 | 130 | 1.420 |
Why?
|
| Host-Pathogen Interactions | 6 | 2016 | 203 | 1.340 |
Why?
|
| STAT1 Transcription Factor | 3 | 2015 | 35 | 1.280 |
Why?
|
| T-Lymphocytes | 7 | 2012 | 378 | 1.270 |
Why?
|
| Interleukin-17 | 5 | 2014 | 53 | 1.190 |
Why?
|
| Fungal Proteins | 5 | 2017 | 143 | 1.150 |
Why?
|
| Cryptococcus | 3 | 2019 | 10 | 1.100 |
Why?
|
| Macrophages, Alveolar | 4 | 2015 | 33 | 1.060 |
Why?
|
| Mice | 36 | 2017 | 6490 | 1.040 |
Why?
|
| Candidiasis, Vulvovaginal | 8 | 2014 | 10 | 0.960 |
Why?
|
| Cryptococcus gattii | 3 | 2017 | 8 | 0.950 |
Why?
|
| Animals | 42 | 2019 | 16695 | 0.900 |
Why?
|
| Immunity, Cellular | 8 | 2015 | 73 | 0.820 |
Why?
|
| Antibodies, Fungal | 6 | 2017 | 24 | 0.810 |
Why?
|
| Antigens, Fungal | 5 | 2017 | 33 | 0.800 |
Why?
|
| Lung Diseases | 3 | 2014 | 62 | 0.780 |
Why?
|
| Interferon-gamma | 6 | 2019 | 268 | 0.740 |
Why?
|
| Disease Models, Animal | 16 | 2017 | 1554 | 0.620 |
Why?
|
| Immunologic Memory | 1 | 2019 | 41 | 0.610 |
Why?
|
| Lectins, C-Type | 2 | 2016 | 37 | 0.600 |
Why?
|
| Neutrophils | 3 | 2012 | 141 | 0.600 |
Why?
|
| Cytokines | 12 | 2017 | 661 | 0.580 |
Why?
|
| Antifungal Agents | 3 | 2016 | 169 | 0.580 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2012 | 17 | 0.580 |
Why?
|
| Female | 34 | 2019 | 24018 | 0.550 |
Why?
|
| Vaccination | 6 | 2019 | 332 | 0.510 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 518 | 0.510 |
Why?
|
| Vagina | 6 | 2012 | 89 | 0.500 |
Why?
|
| Candida albicans | 8 | 2014 | 173 | 0.500 |
Why?
|
| Th1 Cells | 8 | 2014 | 97 | 0.480 |
Why?
|
| Disease Susceptibility | 2 | 2014 | 101 | 0.440 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2012 | 276 | 0.410 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 74 | 0.410 |
Why?
|
| Signal Transduction | 4 | 2015 | 2111 | 0.410 |
Why?
|
| Microbial Viability | 1 | 2012 | 42 | 0.390 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2012 | 11 | 0.380 |
Why?
|
| Mycoses | 1 | 2012 | 31 | 0.380 |
Why?
|
| Lysosomes | 1 | 2012 | 88 | 0.370 |
Why?
|
| Candidiasis | 3 | 2014 | 86 | 0.360 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2017 | 230 | 0.360 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2017 | 458 | 0.360 |
Why?
|
| Peptides | 1 | 2014 | 357 | 0.350 |
Why?
|
| Calcineurin | 3 | 2005 | 22 | 0.340 |
Why?
|
| Biofilms | 2 | 2009 | 178 | 0.320 |
Why?
|
| Mice, Knockout | 5 | 2014 | 1010 | 0.320 |
Why?
|
| Immunodominant Epitopes | 1 | 2009 | 28 | 0.310 |
Why?
|
| Immunity, Innate | 4 | 2019 | 168 | 0.290 |
Why?
|
| Environment | 1 | 2009 | 148 | 0.280 |
Why?
|
| Humans | 19 | 2017 | 42163 | 0.270 |
Why?
|
| Inflammation | 3 | 2019 | 729 | 0.260 |
Why?
|
| Th2 Cells | 5 | 2014 | 63 | 0.230 |
Why?
|
| Nitric Oxide | 3 | 2015 | 381 | 0.230 |
Why?
|
| Virulence | 6 | 2014 | 238 | 0.230 |
Why?
|
| Immunocompromised Host | 2 | 2016 | 26 | 0.230 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 110 | 0.220 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2017 | 140 | 0.220 |
Why?
|
| Vaccines, Attenuated | 3 | 2017 | 75 | 0.220 |
Why?
|
| Survival Analysis | 3 | 2015 | 362 | 0.220 |
Why?
|
| Flow Cytometry | 3 | 2014 | 411 | 0.210 |
Why?
|
| Proteome | 2 | 2017 | 150 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 4 | 2016 | 1804 | 0.210 |
Why?
|
| Lymphocyte Activation | 3 | 2001 | 244 | 0.210 |
Why?
|
| Cell Wall | 2 | 2013 | 55 | 0.200 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2014 | 78 | 0.190 |
Why?
|
| Vaginitis | 1 | 2001 | 1 | 0.180 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 557 | 0.180 |
Why?
|
| Vaccines, Inactivated | 3 | 2017 | 16 | 0.180 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2001 | 2 | 0.180 |
Why?
|
| Immunocompetence | 2 | 2016 | 10 | 0.170 |
Why?
|
| Cell Adhesion Molecules | 1 | 2001 | 84 | 0.170 |
Why?
|
| Chemokines | 3 | 2012 | 97 | 0.170 |
Why?
|
| Cytoprotection | 2 | 2011 | 36 | 0.170 |
Why?
|
| Transcription Factors | 1 | 2005 | 722 | 0.170 |
Why?
|
| Mutation | 7 | 2015 | 1169 | 0.170 |
Why?
|
| Fungi | 2 | 2012 | 103 | 0.150 |
Why?
|
| Adaptive Immunity | 2 | 2016 | 32 | 0.150 |
Why?
|
| Macrophages | 3 | 2015 | 515 | 0.150 |
Why?
|
| Phenotype | 2 | 2019 | 774 | 0.150 |
Why?
|
| Mice, Inbred CBA | 4 | 2002 | 41 | 0.140 |
Why?
|
| Gene Expression Regulation, Fungal | 3 | 2015 | 71 | 0.140 |
Why?
|
| Organisms, Genetically Modified | 2 | 2010 | 5 | 0.140 |
Why?
|
| Cells, Cultured | 3 | 2012 | 1617 | 0.140 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2019 | 184 | 0.140 |
Why?
|
| RNA, Messenger | 2 | 2019 | 1265 | 0.140 |
Why?
|
| Glycolipids | 1 | 2017 | 9 | 0.140 |
Why?
|
| Histones | 1 | 2019 | 194 | 0.140 |
Why?
|
| Vaccines, Synthetic | 1 | 2017 | 78 | 0.140 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 1066 | 0.140 |
Why?
|
| Interleukins | 2 | 2014 | 37 | 0.130 |
Why?
|
| Virulence Factors | 2 | 2014 | 119 | 0.130 |
Why?
|
| Aspergillosis | 1 | 2016 | 2 | 0.130 |
Why?
|
| Aspergillus fumigatus | 1 | 2016 | 13 | 0.130 |
Why?
|
| Immunization | 1 | 2017 | 93 | 0.130 |
Why?
|
| Mouth Mucosa | 2 | 2014 | 30 | 0.120 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 522 | 0.120 |
Why?
|
| Administration, Intranasal | 2 | 2014 | 89 | 0.120 |
Why?
|
| Immunoglobulins | 2 | 2009 | 39 | 0.120 |
Why?
|
| Hyphae | 1 | 2015 | 36 | 0.120 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 52 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2015 | 128 | 0.110 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2014 | 9 | 0.110 |
Why?
|
| Urothelium | 1 | 2014 | 8 | 0.110 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2014 | 2 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 649 | 0.110 |
Why?
|
| Meningoencephalitis | 1 | 2014 | 14 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 15 | 0.110 |
Why?
|
| Proteomics | 1 | 2017 | 363 | 0.110 |
Why?
|
| Immunoblotting | 1 | 2014 | 181 | 0.110 |
Why?
|
| Cell Fractionation | 1 | 2013 | 30 | 0.110 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 70 | 0.110 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 64 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 131 | 0.100 |
Why?
|
| Leukocytes | 2 | 2015 | 79 | 0.100 |
Why?
|
| Cytoplasm | 1 | 2013 | 154 | 0.100 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 658 | 0.100 |
Why?
|
| Osmosis | 1 | 2012 | 9 | 0.100 |
Why?
|
| Intracellular Space | 1 | 2012 | 37 | 0.100 |
Why?
|
| Cell Extracts | 1 | 2012 | 15 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2014 | 574 | 0.100 |
Why?
|
| Immunophenotyping | 1 | 2012 | 57 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 53 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 79 | 0.100 |
Why?
|
| Cathepsin B | 1 | 2012 | 35 | 0.100 |
Why?
|
| Models, Molecular | 1 | 2016 | 875 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2011 | 46 | 0.090 |
Why?
|
| Autopsy | 1 | 2011 | 46 | 0.090 |
Why?
|
| New Mexico | 1 | 2011 | 36 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2012 | 232 | 0.090 |
Why?
|
| Congresses as Topic | 1 | 2011 | 49 | 0.090 |
Why?
|
| Phosphorylation | 1 | 2014 | 973 | 0.090 |
Why?
|
| Tetracycline | 1 | 2011 | 17 | 0.090 |
Why?
|
| Lymphocyte Depletion | 1 | 2011 | 13 | 0.090 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2011 | 24 | 0.090 |
Why?
|
| Candidiasis, Oral | 2 | 2002 | 23 | 0.090 |
Why?
|
| Temperature | 2 | 2009 | 314 | 0.080 |
Why?
|
| Saliva | 2 | 2002 | 115 | 0.080 |
Why?
|
| Transgenes | 1 | 2010 | 65 | 0.080 |
Why?
|
| Interleukin-4 | 3 | 2005 | 75 | 0.080 |
Why?
|
| Genotype | 1 | 2011 | 796 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1058 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2009 | 158 | 0.070 |
Why?
|
| Carbon Dioxide | 1 | 2009 | 86 | 0.070 |
Why?
|
| Phylogeny | 1 | 2011 | 740 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 385 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 456 | 0.070 |
Why?
|
| Brain | 2 | 2015 | 1452 | 0.070 |
Why?
|
| Mice, Inbred A | 1 | 2007 | 7 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 151 | 0.070 |
Why?
|
| Cell Line | 2 | 2014 | 1416 | 0.060 |
Why?
|
| Flocculation | 1 | 2005 | 6 | 0.060 |
Why?
|
| tert-Butylhydroperoxide | 1 | 2005 | 6 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2009 | 548 | 0.060 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2002 | 4 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2010 | 1586 | 0.060 |
Why?
|
| Fluconazole | 1 | 2004 | 41 | 0.060 |
Why?
|
| Phagocytosis | 1 | 2005 | 83 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2005 | 95 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2003 | 80 | 0.050 |
Why?
|
| Blood | 1 | 2003 | 37 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2003 | 158 | 0.050 |
Why?
|
| Stomatitis, Denture | 1 | 2002 | 2 | 0.050 |
Why?
|
| Body Fluids | 1 | 2002 | 18 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2002 | 76 | 0.050 |
Why?
|
| HIV Seronegativity | 2 | 2002 | 41 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2002 | 63 | 0.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2002 | 45 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1559 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2003 | 403 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2002 | 87 | 0.050 |
Why?
|
| Enterotoxins | 1 | 2002 | 33 | 0.050 |
Why?
|
| Bacterial Toxins | 1 | 2002 | 50 | 0.050 |
Why?
|
| Nitrogen Oxides | 1 | 2001 | 7 | 0.050 |
Why?
|
| Time Factors | 2 | 2003 | 1848 | 0.050 |
Why?
|
| Mucoproteins | 1 | 2001 | 1 | 0.050 |
Why?
|
| L-Selectin | 1 | 2001 | 2 | 0.050 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2001 | 5 | 0.050 |
Why?
|
| Integrin alpha4beta1 | 1 | 2001 | 5 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 683 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 117 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2001 | 31 | 0.040 |
Why?
|
| Integrins | 1 | 2001 | 54 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2001 | 58 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 253 | 0.040 |
Why?
|
| Cricetinae | 1 | 2001 | 241 | 0.040 |
Why?
|
| Middle Aged | 4 | 2011 | 11819 | 0.040 |
Why?
|
| Escherichia coli Proteins | 1 | 2002 | 133 | 0.040 |
Why?
|
| Chlamydia trachomatis | 1 | 2001 | 69 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 116 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2000 | 111 | 0.040 |
Why?
|
| Estradiol | 1 | 2002 | 269 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2000 | 59 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2005 | 990 | 0.040 |
Why?
|
| Chlamydia Infections | 1 | 2001 | 199 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 44 | 0.040 |
Why?
|
| Gene Expression | 1 | 2000 | 692 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 1998 | 196 | 0.030 |
Why?
|
| Drug Resistance, Fungal | 2 | 2008 | 33 | 0.030 |
Why?
|
| Laccase | 1 | 2015 | 7 | 0.030 |
Why?
|
| Kidney | 2 | 2011 | 363 | 0.030 |
Why?
|
| Male | 3 | 2011 | 22779 | 0.030 |
Why?
|
| Eosinophils | 1 | 2014 | 22 | 0.030 |
Why?
|
| Goblet Cells | 1 | 2014 | 12 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2014 | 78 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 295 | 0.030 |
Why?
|
| Calgranulin A | 1 | 2012 | 1 | 0.020 |
Why?
|
| Interleukin-23 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Calgranulin B | 1 | 2012 | 4 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 661 | 0.020 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2011 | 20 | 0.020 |
Why?
|
| Response Elements | 1 | 2011 | 55 | 0.020 |
Why?
|
| Doxycycline | 1 | 2011 | 32 | 0.020 |
Why?
|
| Interleukin-12 | 2 | 2002 | 46 | 0.020 |
Why?
|
| Spleen | 1 | 2011 | 199 | 0.020 |
Why?
|
| Interleukin-2 | 2 | 2002 | 90 | 0.020 |
Why?
|
| Interleukin-10 | 2 | 2002 | 86 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 928 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 534 | 0.020 |
Why?
|
| Formazans | 1 | 2008 | 5 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2004 | 43 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2004 | 15 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2003 | 18 | 0.010 |
Why?
|
| Denture, Partial | 1 | 2002 | 1 | 0.010 |
Why?
|
| Denture, Complete | 1 | 2002 | 2 | 0.010 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2002 | 5 | 0.010 |
Why?
|
| Administration, Rectal | 1 | 2002 | 18 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 113 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 49 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2001 | 34 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2001 | 200 | 0.010 |
Why?
|
| Premenopause | 1 | 2001 | 109 | 0.010 |
Why?
|
| Adult | 3 | 2002 | 13458 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2003 | 324 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 207 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1998 | 733 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 1998 | 475 | 0.010 |
Why?
|
| Aged | 1 | 2002 | 7982 | 0.000 |
Why?
|